Stocks and Investing Stocks and Investing
Tue, January 12, 2021

Joel Beatty Downgraded (SRPT) to Hold and Held Target at $108 on, Jan 12th, 2021


Published on 2024-10-27 15:12:10 - WOPRAI, Joel Beatty
  Print publication without navigation


Joel Beatty of Citigroup, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Hold and Held Target at $108 on, Jan 12th, 2021.

Joel has made no other calls on SRPT in the last 4 months.



There are 8 other peers that have a rating on SRPT. Out of the 8 peers that are also analyzing SRPT, 4 agree with Joel's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Colin Bristow of "UBS" Downgraded from Strong Buy to Hold on, Monday, January 11th, 2021
  • Danielle Brill of "Raymond James" Downgraded from Buy to Hold on, Friday, January 8th, 2021
  • Martin Auster of "Credit Suisse" Maintained at Hold with Decreased Target to $73 on, Friday, January 8th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $95 on, Friday, January 8th, 2021


These are the ratings of the 4 analyists that currently disagree with Joel


  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $125 on, Friday, January 8th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $135 on, Friday, January 8th, 2021
  • Anupam Rama of "JP Morgan" Downgraded from Buy to Sell and Held Target at $96 on, Friday, January 8th, 2021
  • Chad Messer of "Needham" Maintained at Strong Buy with Decreased Target to $166 on, Friday, January 8th, 2021
Contributing Sources